Drug/Small Molecule:
celecoxib

PharmGKB contains no dosing guidelines for this drug/small molecule. To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB gathers information regarding PGx on FDA drug labels from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels", and from FDA-approved FDA and EMA-approved (European Medicines Agency) EMA labels brought to our attention. Excerpts from the label and downloadable highlighted label PDFs are manually curated by PharmGKB.

Please note that some drugs may have been removed from or added to the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" without our knowledge. We periodically check the table for additions to this table and update PharmGKB accordingly.

There is currently no such list for European drug labels - we are working with the EMA to establish a list of European Public Assessment Reports (EPAR)s that contain PGx information. We are constructing this list by initially searching for drugs for which we have PGx-containing FDA drug labels - of these 44 EMA EPARs were identified and are being curated for pgx information.

We welcome any information regarding drug labels containing PGx information approved by the FDA, EMA or other Medicine Agencies around the world - please contact feedback.


last updated 10/25/2013

FDA Label for celecoxib and CYP2C9

This label is on the FDA Biomarker List
Actionable PGx

Summary

Celecoxib is metabolized primarily by CYP2C9. Patients who are known or suspected to be poor CYP2C9 metabolizers should be administered celecoxib with caution. Consider a dose reduction by 50% (or alternative management for juvenile rheumatoid arthritis (JRA)) in patients who are known or suspected to be CYP2C9 poor metabolizers.

Annotation

Excerpt from the CELEBREX drug label:

Poor Metabolizers of CYP2C9 Substrates: Patients who are known or suspected to be poor CYP2C9 metabolizers based on previous history/experience with other CYP2C9 substrates (such as warfarin, phenytoin) should be administered celecoxib with caution. Consider starting treatment at half the lowest recommended dose in poor metabolizers. Consider using alternative management in JRA patients who are poor metabolizers.

Celecoxib metabolism is primarily mediated via CYP2C9.

CYP2C9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the CYP2C9*2 and CYP2C9*3 polymorphisms. Limited data from 4 published reports that included a total of 8 subjects with the homozygous CYP2C9*3/*3 genotype showed celecoxib systemic levels that were 3- to 7-fold higher in these subjects compared to subjects with CYP2C9*1/*1 or *I/*3 genotypes. The pharmacokinetics of celecoxib have not been evaluated in subjects with other CYP2C9 polymorphisms, such as *2, *5, *6, *9 and *11. It is estimated that the frequency of the homozygous *3/*3 genotype is 0.3% to 1.0% in various ethnic groups.

Consider a dose reduction by 50% (or alternative management for JRA) in patients who are known or suspected to be CYP2C9 poor metabolizers.

For the complete drug label text with sections containing pharmacogenetic information highlighted, see the Celecoxib drug label.

*Disclaimer: The contents of this page have not been endorsed by the FDA and are the sole responsibility of PharmGKB.

Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Adenoma
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Arthritis
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Colorectal Neoplasms
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • Hemorrhage
    • Warnings section, Adverse reactions section
    • source: PHONT
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    • Adverse reactions section
    • source: PHONT
  • Liver Neoplasms
    • Warnings section, Adverse reactions section
    • source: PHONT
  • Neoplasms
    • Indications & usage section, Warnings section, Adverse reactions section
    • source: PHONT
  • CYP2C9
    • Dosage & administration section, Drug interactions section, Pediatric use section, Clinical pharmacology section, Pharmacokinetics section, Use in specific populations section, dosage, metabolism/PK
    • source: FDA Label
  • CYP2D6
    • Drug interactions section, metabolism/PK
    • source: PharmGKB
  • CYP2D6
    • Drug interactions section, metabolism/PK
    • source: FDA Label


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Gene?

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

Gene ? Variant?
(138)
Alternate Names / Tag SNPs ? Drugs ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2C8 *1A N/A N/A N/A
No VIP available No VIP available VA CYP2C8 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C8 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C8 *4 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *1 N/A N/A N/A
VIP No VIP available VA CYP2C9 *2 N/A N/A N/A
VIP No VIP available VA CYP2C9 *3 N/A N/A N/A
rs1057910 1075A>C, 47545517A>C, 47639A>C, 96741053A>C, CYP2C9*3, CYP2C9*3:Ile359Leu, CYP2C9: I359L, CYP2C9:359Ile>Leu, CYP2C9:Ile359Leu, Ile359Leu, mRNA 11A>C
A > C
Missense
Ile359Leu
No VIP available No Clinical Annotations available VA
rs11078659 233+9171C>T, 6507318G>A, 6903944G>A, 951+146G>A
G > A
Intronic
rs1799853 430C>T, 47506511C>T, 8633C>T, 96702047C>T, Arg144Cys, CYP2C9*2, CYP2C9:144Arg>Cys, CYP2C9:Arg144Cys, mRNA 455C>T
C > T
Missense
Arg144Cys
VIP No Clinical Annotations available No Variant Annotations available
rs20417 -899G>C, 186650321C>G, 38138963C>G, 4239G>C, COX-2 G-765C, PTGS2:-765G>C
C > G
5' Flanking
No VIP available No Clinical Annotations available VA
rs2302821 *9T>G, 132501881A>C, 61666413A>C
A > C
3' UTR
No VIP available No Clinical Annotations available VA
rs3842787 -248C>T, -249C>T, -278C>T, 125133507C>T, 130C>T, 356C>T, 50C>T, 5279C>T, 54298039C>T, C>T, PTGS1: P17L, Pro17Leu
C > T
5' UTR
Pro17Leu
No VIP available No Clinical Annotations available VA
rs4133101 -1057T>C, 40669567T>C, 40679567T>C
T > C
5' Flanking
No VIP available No Clinical Annotations available VA
rs5273 10792T>C, 1532T>C, 186643768A>G, 38132410A>G, Val511Ala
A > G
Missense
Val511Ala
No VIP available No Clinical Annotations available VA
rs7518660 37657361G>A, 58275G>A, 67685443G>A, 955+30G>A
G > A
Intronic
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 138
2D structure from PubChem
provided by PubChem

Overview

Generic Names
  • Celocoxib
  • celecoxib
Trade Names
  • Celebra
  • Celebrex
  • Onsenal
Brand Mixture Names

PharmGKB Accession Id:
PA448871

Description

Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form.

Source: Drug Bank

Indication

For relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis. Unlike most NSAIDs, which inhibit both types of cyclooxygenases (COX-1 and COX-2), celecoxib is a selective noncompetitive inhibitor of cyclooxygenase-2 (COX-2) enzyme. It binds with its polar sulfonamide side chain to a hydrophilic side pocket region close to the active COX-2 binding site. Both COX-1 and COX-2 catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane.

Source: Drug Bank

Pharmacology

Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is classified as a nonsteroidal anti-inflammatory drug (NSAID). Celecoxib is used to treat rheumatoid arthritis, osteoarthritis, and familial adenomatous polyposis (FAP). Because of its lack of platelet effects, celecoxib is not a substitute for aspirin for cardiovascular prophylaxis. It is not known if there are any effects of celecoxib on platelets that may contribute to the increased risk of serious cardiovascular thrombotic adverse events associated with the use of celecoxib. Inhibition of PGE2 synthesis may lead to sodium and water retention through increased reabsorption in the renal medullary thick ascending loop of Henle and perhaps other segments of the distal nephron. In the collecting ducts, PGE2 appears to inhibit water reabsorption by counteracting the action of antidiuretic hormone.

Source: Drug Bank

Food Interaction

Taking this product with a high-fat meal will delay the Cmax, but total absorption will be increased by 10 to 20%.|Take without regard to meals.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Hepatic. Celecoxib metabolism is primarily mediated via cytochrome P450 2C9. Three metabolites, a primary alcohol, the corresponding carboxylic acid and its glucuronide conjugate, have been identified in human plasma. These metabolites are inactive as COX-1 or COX-2 inhibitors.

Source: Drug Bank

Protein Binding

97%, primarily to albumin and, to a lesser extent, a 1-acid glycoprotein.

Source: Drug Bank

Absorption

Well absorbed in the gastrointestinal tract. When taken with a high fat meal, peak plasma levels are delayed for about 1 to 2 hours with an increase in total absorption (AUC) of 10% to 20%.

Source: Drug Bank

Half-Life

Approximately 11 hours.

Source: Drug Bank

Toxicity

Symptoms of overdose include breathing difficulties, coma, drowsiness, gastrointestinal bleeding, high blood pressure, kidney failure, nausea, sluggishness, stomach pain, and vomiting.

Source: Drug Bank

Clearance

  • 500 mL/min

Source: Drug Bank

Route of Elimination

Celecoxib is eliminated predominantly by hepatic metabolism with little (<3%) unchanged drug recovered in the urine and feces.

Source: Drug Bank

Volume of Distribution

  • 400 L

Source: Drug Bank

Chemical Properties

Chemical Formula

C17H14F3N3O2S

Source: Drug Bank

Isomeric SMILES

Cc1ccc(cc1)c2cc(nn2c3ccc(cc3)S(=O)(=O)N)C(F)(F)F

Source: OpenEye

Canonical SMILES

CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F

Source: Drug Bank

Average Molecular Weight

381.372

Source: Drug Bank

Monoisotopic Molecular Weight

381.075882012

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Celecoxib Pathway, Pharmacodynamics
    Stylized cell depicting the mechanism of action of celecoxib and candidate genes interacting with celecoxib and involved in the regulation of cell cycle, apoptosis and angiogenesis by celecoxib.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
PDPK1 (source: Drug Bank)
PTGS2 (source: Drug Bank)

Drug Interactions

Drug Description
acenocoumarol Increases the anticoagulant effect (source: Drug Bank)
acenocoumarol Celecoxib may increase the anticoagulant effect of acenocoumarol. (source: Drug Bank)
anisindione Celecoxib may increase the anticoagulant effect of anisindione. (source: Drug Bank)
dicumarol Increases the anticoagulant effect (source: Drug Bank)
dicumarol Celecoxib may increase the anticoagulant effect of dicumarol. (source: Drug Bank)
fluconazole Fluconazole increases the effect of celecoxib (source: Drug Bank)
fluconazole Fluconazole increases the effect of celecoxib (source: Drug Bank)
lithium The COX-2 inhibitor increases serum levels of lithium (source: Drug Bank)
lithium The COX-2 inhibitor increases serum levels of lithium (source: Drug Bank)
rifampin Decreased levels/effect of the NSAID (source: Drug Bank)
rifampin Rifampin, a CYP2C9 inducer, may increase the metabolism of celecoxib. (source: Drug Bank)
warfarin Increases the anticoagulant effect (source: Drug Bank)
warfarin Celecoxib may increase the anticoagulant effect of warfarin. (source: Drug Bank)
celecoxib Increases the effect of celecoxib (source: Drug Bank)
celecoxib Increases the effect of celecoxib (source: Drug Bank)
celecoxib The COX-2 inhibitor increases serum levels of lithium (source: Drug Bank)
celecoxib The COX-2 inhibitor increases serum levels of lithium (source: Drug Bank)
celecoxib Decreased levels/effect of the NSAID (source: Drug Bank)
celecoxib Rifampin, a strong CYP2C9 inducer, may decrease the serum levels of celecoxib by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects if rifampin is initiated, discontinued or dose changed. (source: Drug Bank)
celecoxib Concomitant use of Telmisartan and Celecoxib may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. (source: Drug Bank)
celecoxib Concomitant use of Telmisartan and Celecoxib may increase the risk of acute renal failure and hyperkalemia. Monitor renal function at the beginning and during treatment. (source: Drug Bank)
celecoxib The NSAID, Celecoxib, may antagonize the antihypertensive effect of Timolol. (source: Drug Bank)
celecoxib The NSAID, Celecoxib, may antagonize the antihypertensive effect of Timolol. (source: Drug Bank)
celecoxib Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Celecoxib. Consider alternate therapy or monitor for changes in Celecobix therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. (source: Drug Bank)
celecoxib Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Celecoxib. Consider alternate therapy or monitor for changes in Celecobix therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. (source: Drug Bank)
celecoxib The NSAID, Celecoxib, may reduce the antihypertensive effect of Trandolapril. Consider alternate therapy or monitor for changes in Trandolapril efficacy if Celecoxib is initiated, discontinued or dose changed. (source: Drug Bank)
celecoxib The prostacyclin analogue, Treprostinil, may increase the risk of bleeding when combined with the NSAID, Celecoxib. Monitor for increased bleeding during concomitant thearpy. (source: Drug Bank)
celecoxib The moderate CYP2C8 inhibitor, Celecoxib, may decrease the metabolism and clearance of oral Tretinoin. Monitor for changes in Tretinoin effectiveness and adverse/toxic effects if Celecoxib is initiated, discontinued to dose changed. (source: Drug Bank)

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to celecoxib: 54

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Germline Variants and Advanced Colorectal Adenomas: Adenoma Prevention with Celecoxib Trial Genome-wide Association Study. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013. Wang Jiping, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Evaluation of the relationship between polymorphisms in CYP2C8 and CYP2C9 and the pharmacokinetics of celecoxib. Journal of clinical pharmacology. 2013. Prieto-Pérez Rocío, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications. European journal of clinical pharmacology. 2013. Yiannakopoulou Eugenia. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study. Pharmacogenetics and genomics. 2013. Kraus Sarah, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. Pharmacogenomics. 2011. Patterson Scott D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coprescription of tamoxifen and medications that inhibit CYP2D6. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. Journal of clinical pharmacology. 2010. Borges Silvana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Cytochrome P450 2C9-CYP2C9. Pharmacogenetics and genomics. 2010. Van Booven Derek, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ADME pharmacogenetics: current practices and future outlook. Expert opinion on drug metabolism & toxicology. 2009. Grossman Iris. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?. Expert opinion on drug metabolism & toxicology. 2009. Agúndez José A G, et al. PubMed
Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma. Gastroenterology. 2009. Chan Andrew T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prediction of the effects of genetic polymorphism on the pharmacokinetics of CYP2C9 substrates from in vitro data. Pharmaceutical research. 2009. Kusama Makiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors. Proceedings of the National Academy of Sciences of the United States of America. 2009. Yan Min, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Machine learning methods and docking for predicting human pregnane X receptor activation. Chemical research in toxicology. 2008. Khandelwal Akash, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical use and pharmacological properties of selective COX-2 inhibitors. European journal of clinical pharmacology. 2008. Shi Shaojun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance. Pharmacogenomics. 2007. Skarke Carsten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
GADD153 mediates celecoxib-induced apoptosis in cervical cancer cells. Carcinogenesis. 2007. Kim Su-Hyeong, et al. PubMed
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology. 2007. Pilotto Alberto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CYP2C9 structure-metabolism relationships: substrates, inhibitors, and metabolites. Journal of medicinal chemistry. 2007. Ahlström Marie M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Intracellular actions of group IIA secreted phospholipase A2 and group IVA cytosolic phospholipase A2 contribute to arachidonic acid release and prostaglandin production in rat gastric mucosal cells and transfected human embryonic kidney cells. The Journal of biological chemistry. 2006. Ni Zhanglin, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. American journal of hematology. 2006. Zhang Guang-Sen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3. Clinical pharmacology and therapeutics. 2006. Lundblad Mia Sandberg, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production. Clinical pharmacology and therapeutics. 2006. Skarke Carsten, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib leads to G2/M arrest by induction of p21 and down-regulation of cyclin B1 expression in a p53-independent manner. European journal of cancer (Oxford, England : 1990). 2006. Dvory-Sobol Hadas, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology. 2006. Fries Susanne, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib induces anoikis in human colon carcinoma cells associated with the deregulation of focal adhesions and nuclear translocation of p130Cas. International journal of cancer. Journal international du cancer. 2006. Casanova Isolda, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005. Patel Manish I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005. Cui Wei, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical consequences of cytochrome P450 2C9 polymorphisms. Clinical pharmacology and therapeutics. 2005. Kirchheiner Julia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cytochrome P450 2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. Clinical pharmacology and therapeutics. 2005. Stempak Diana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2005. Maier Thorsten Jürgen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. The New England journal of medicine. 2005. Solomon Scott D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arachidonic acid release from mammalian cells transfected with human groups IIA and X secreted phospholipase A(2) occurs predominantly during the secretory process and with the involvement of cytosolic phospholipase A(2)-alpha. The Journal of biological chemistry. 2004. Mounier Carine M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochemical and biophysical research communications. 2004. Levitt Randy J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Sp1 transcription factor activity. Cancer research. 2004. Wei Daoyan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer research. 2004. Han Chang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. International journal of cancer. Journal international du cancer. 2004. Peluffo Guillermo D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic predisposition to acute gastrointestinal bleeding after NSAIDs use. British journal of pharmacology. 2004. Martínez Carmen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clinical pharmacology and therapeutics. 2003. Werner Ulrike, et al. PubMed
Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. Pharmacogenetics. 2003. Kirchheiner Julia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib activates a novel mitochondrial apoptosis signaling pathway. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2003. Jendrossek Verena, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World journal of gastroenterology : WJG. 2003. Wu Gao-Song, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology (Baltimore, Md.). 2002. Kern Michael André, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. The Journal of biological chemistry. 2002. Arico Sebastien, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prostaglandins and leukotrienes: advances in eicosanoid biology. Science (New York, N.Y.). 2001. Funk C D. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics. Pharmacogenetics. 2001. Tang C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2001. Grösch S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. The Journal of biological chemistry. 2000. Murakami M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. The Journal of pharmacology and experimental therapeutics. 2000. Tang C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Celecoxib, a COX-2--specific inhibitor: the clinical data. American journal of orthopedics (Belle Mead, N.J.). 1999. Fort J. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. The Journal of biological chemistry. 1996. Smith W L, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0025-1515-01
DrugBank:
DB00482
PDB:
CEL
ChEBI:
3520
KEGG Compound:
C07589
KEGG Drug:
D00567
PubChem Compound:
2662
PubChem Substance:
205043
46505596
Drugs Product Database (DPD):
2239941
BindingDB:
11639
ChemSpider:
2562
HET:
CEL
Therapeutic Targets Database:
DAP000737
FDA Drug Label at DailyMed:
8d52185d-421f-4e34-8db7-f7676db2a226

Clinical Trials

These are trials that mention celecoxib and are related to either pharmacogenetics or pharmacogenomics.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, Open Eye Scientific Software.